Jump to content

Tryptamine

From Wikipedia, the free encyclopedia
This article is about the specific substance. For the class of substances, see substituted tryptamine.
Tryptamine
Names
Preferred IUPAC name
2-(1H-Indol-3-yl)ethan-1-amine
Identifiers
3D model (JSmol)
125513
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.000.464 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C10H12N2/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6,11H2 checkY
    Key: APJYDQYYACXCRM-UHFFFAOYSA-N ☒N
  • InChI=1/C10H12N2/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6,11H2
    Key: APJYDQYYACXCRM-UHFFFAOYAU
  • c1ccc2c(c1)c(c[nH]2)CCN
Properties[1]
C10H12N2
Molar mass 160.220 g·mol−1
Appearance white to orange needles
Melting point 118˚C
Boiling point 137 °C (279 °F; 410 K) (0.15 mmHg)
negligible solubility in water
Pharmacology
Intravenous[2][3][4]
Pharmacokinetics:
Very low
Very rapid (oxidative deamination by MAOTooltip monoamine oxidase)[5][6][3][4]
Indole-3-acetic acid (IAA)
Very rapid[5][6][3][4]
Very short[5][6][3][4]
Very short[5][6][3][4]
Urine[4][7][8]
Legal status
  • Legal or unregulated
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Tryptamine is an indolamine metabolite of the essential amino acid tryptophan.[9][10] The chemical structure is defined by an indole—a fused benzene and pyrrole ring, and a 2-aminoethyl group at the second carbon (third aromatic atom, with the first one being the heterocyclic nitrogen).[9] The structure of tryptamine is a shared feature of certain aminergic neuromodulators including melatonin, serotonin, bufotenin and psychedelic derivatives such as dimethyltryptamine (DMT), psilocybin, psilocin and others.[11][12][13]

Tryptamine has been shown to activate serotonin receptors[6][14] and trace amine-associated receptors expressed in the mammalian brain, and regulates the activity of dopaminergic, serotonergic and glutamatergic systems.[15][16] In the human gut, symbiotic bacteria convert dietary tryptophan to tryptamine, which activates 5-HT4 receptors and regulates gastrointestinal motility.[10][17][18]

Multiple tryptamine-derived drugs have been developed to treat migraines, while trace amine-associated receptors are being explored as a potential treatment target for neuropsychiatric disorders.[19][20][21]

Natural occurrences

[edit]

For a list of plants, fungi and animals containing tryptamines, see List of psychoactive plants and List of naturally occurring tryptamines.

Mammalian brain

[edit]

Endogenous levels of tryptamine in the mammalian brain are less than 100 ng per gram of tissue.[12][16] However, elevated levels of trace amines have been observed in patients with certain neuropsychiatric disorders taking medications, such as bipolar depression and schizophrenia.[22]

Mammalian gut microbiome

[edit]

Tryptamine is relatively abundant in the gut and feces of humans and rodents.[10][17] Commensal bacteria, including Ruminococcus gnavus and Clostridium sporogenes in the gastrointestinal tract, possess the enzyme tryptophan decarboxylase, which aids in the conversion of dietary tryptophan to tryptamine.[10] Tryptamine is a ligand for gut epithelial serotonin type 4 (5-HT4) receptors and regulates gastrointestinal electrolyte balance through colonic secretions.[17]

Metabolism

[edit]

Biosynthesis

[edit]

To yield tryptamine in vivo, tryptophan decarboxylase removes the carboxylic acid group on the α-carbon of tryptophan.[12] Synthetic modifications to tryptamine can produce serotonin and melatonin; however, these pathways do not occur naturally as the main pathway for endogenous neurotransmitter synthesis.[23]

Catabolism

[edit]

Monoamine oxidases A and B are the primary enzymes involved in tryptamine metabolism to produce indole-3-acetaldehyde, however it is unclear which isoform is specific to tryptamine degradation.[24]

Figure

[edit]
Conversion of tryptophan to tryptamine, followed by its degradation to indole-3-acetic acid.

Biological activity

[edit]
Tryptamine target activities
Target Affinity (Ki, nM) Species
5-HT1A 105 (Ki)
>10,000 (EC50Tooltip half-maximal effective concentration)		 Human
Human
5-HT1B 36–525 Human
5-HT1D 23–521 Human
5-HT1E 2,559 Human
5-HT1F 2,409 Human
5-HT2A 89–3,162 (Ki)
7.4–257 (EC50)		 Human
Human
5-HT2B 25–102 (Ki)
29.5 (EC50)		 Human
Human
5-HT2C 46–3,000 (Ki)
45.7 (EC50)		 Human
Human
5-HT3 ND ND
5-HT4 >10,000 Mouse
5-HT5A ND ND
5-HT6 70–438 Human
5-HT7 148–158 Human
α2A 19,000 Rat
TAAR1Tooltip Human trace amine-associated receptor 1 1,084 (Ki)
2,210–21,000 (EC50)		 Human
Human
SERTTooltip Serotonin transporter 32.6 (EC50) a Rat
NETTooltip Norepinephrine transporter 716 (EC50) a Rat
DATTooltip Dopamine transporter 164 (EC50) a Rat
Note: The smaller the value, the more avidly the compound binds to or activates the site. Footnotes: a = Neurotransmitter release. Refs: Main: [25][26] Additional: [27][6][28][29]

Serotonin receptor agonist

[edit]

Tryptamine is known to act as a serotonin receptor agonist, although its potency is limited by rapid inactivation by monoamine oxidases.[5][6][14][30][31] It has specifically been found to act as a full agonist of the serotonin 5-HT2A receptor (EC50Tooltip half-maximal effective concentration = 7.36 ± 0.56 nM; Emax = 104 ± 4%).[6] Tryptamine was of much lower potency in stimulating the 5-HT2A receptor β-arrestin pathway (EC50 = 3,485 ± 234 nM; Emax = 108 ± 16%).[6] In contrast to the 5-HT2A receptor, tryptamine was found to be inactive at the serotonin 5-HT1A receptor.[6]

Gastrointestinal motility

[edit]

Tryptamine produced by mutualistic bacteria in the human gut activates serotonin GPCRs ubiquitously expressed along the colonic epithelium.[17] Upon tryptamine binding, the activated 5-HT4 receptor undergoes a conformational change which allows its Gs alpha subunit to exchange GDP for GTP, and its liberation from the 5-HT4 receptor and βγ subunit.[17] GTP-bound Gs activates adenylyl cyclase, which catalyzes the conversion of ATP into cyclic adenosine monophosphate (cAMP).[17] cAMP opens chloride and potassium ion channels to drive colonic electrolyte secretion and promote intestinal motility.[18][32]

Tryptamine promotes intestinal motility by activating serotonin receptors in the gut to increase colonic secretions.

TAAR1 agonist

[edit]
TAAR1 affinities and activational potencies of tryptamines[27]
Tryptamine Human TAAR1 Mouse TAAR1 Rat TAAR1
EC50 Ki EC50 Ki EC50 Ki
Tryptamine 21 N/A 2.7 1.4 0.41 0.13
Serotonin >50 N/A >50 N/A 5.2 N/A
Psilocin >30 N/A 2.7 17 0.92 1.4
Dimethyltryptamine >10 N/A 1.2 3.3 1.5 22
Notes: (1) EC50 and Ki values are in micromolar (μM). (2) EC50 reflects the concentration required to elicit 50% of the maximum TAAR1 response. (3) The smaller the Ki value, the stronger the compound binds to the receptor.

Tryptamine can weakly activate the trace amine-associated receptor, TAAR1 (hTAAR1 in humans).[33][15][34] Limited studies have considered tryptamine to be a trace neuromodulator capable of regulating the activity of neuronal cell responses without binding to the associated postsynaptic receptors.[34][22]

hTAAR1 is a stimulatory G-protein coupled receptor (GPCR) that is weakly expressed in the intracellular compartment of both pre- and postsynaptic neurons.[16] Tryptamine and other hTAAR1 agonists can increase neuronal firing by inhibiting neurotransmitter recycling through cAMP-dependent phosphorylation of the monoamine reuptake transporter.[35][22] This mechanism increases the amount of neurotransmitter in the synaptic cleft, subsequently increasing postsynaptic receptor binding and neuronal activation.[22] Conversely, when hTAAR1 are colocalized with G protein-coupled inwardly-rectifying potassium channels (GIRKs), receptor activation reduces neuronal firing by facilitating membrane hyperpolarization through the efflux of potassium ions.[22] The balance between the inhibitory and excitatory activity of hTAAR1 activation highlights the role of tryptamine in the regulation of neural activity.[36]

Activation of hTAAR1 is under investigation as a novel treatment for depression, addiction, and schizophrenia.[16] hTAAR1 is primarily expressed in brain structures associated with dopamine systems, such as the ventral tegmental area (VTA) and serotonin systems in the dorsal raphe nuclei (DRN).[16] Additionally, the hTAAR1 gene is localized at 6q23.2 on the human chromosome, which is a susceptibility locus for mood disorders and schizophrenia.[27] Activation of TAAR1 suggests a potential novel treatment for neuropsychiatric disorders, as TAAR1 agonists produce anti-depressive activity, increased cognition, reduced stress and anti-addiction effects.[36][27]

Monoamine releasing agent

[edit]
Monoamine release of tryptamine and related agents (EC50Tooltip Half maximal effective concentration, nM)
Compound 5-HTTooltip Serotonin NETooltip Norepinephrine DATooltip Dopamine Ref
Tryptamine 32.6 716 164 [6][28]
Serotonin 44.4 >10,000 ≥1,960 [37][38]
Phenethylamine >10,000 10.9 39.5 [39][40][38]
Tyramine 2,775 40.6 119 [37][38]
5-Methoxytryptamine 2,169 >10,000 >10,000 [28]
N-Methyltryptamine 22.4 733 321 [6]
Dimethyltryptamine 114 4,166 >10,000 [6]
Psilocin 561 >10,000 >10,000 [41][6]
Bufotenin 30.5 >10,000 >10,000 [6]
5-MeO-DMT >10,000 >10,000 >10,000 [42]
α-Methyltryptamine 21.7–68 79–112 78.6–180 [42]
α-Ethyltryptamine 23.2 640 232 [28]
D-Amphetamine 698–1,765 6.6–7.2 5.8–24.8 [37][43]
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs: [44][45]

Tryptamine has been found to act as a monoamine releasing agent.[5][6][28] It is a releaser of serotonin, dopamine, and norepinephrine, in that order of potency (EC50 = 32.6 ± 2.6 nM, 164 ± 16 nM, and 716 ± 46 nM, respectively).[5][6][28]

Monoaminergic activity enhancer

[edit]

Tryptamine is a monoaminergic activity enhancer (MAE) of serotonin, norepinephrine, and dopamine in addition to its serotonin receptor agonism.[46][47] That is, it enhances the action potential-mediated release of these monoamine neurotransmitters.[46][47] The MAE actions of tryptamine and other MAEs may be mediated by TAAR1 agonism.[48][49] Synthetic and more potent MAEs like benzofuranylpropylaminopentane (BPAP) and indolylpropylaminopentane (IPAP) have been derived from tryptamine.[46][47][50][51][52]

Effects in animals and humans

[edit]

In a published clinical study, tryptamine, at a total dose of 23 to 277 mg by intravenous infusion, produced hallucinogenic effects or perceptual disturbances similar to those of small doses of lysergic acid diethylamide (LSD).[2][3][6][4] It also produced other LSD-like effects, including pupil dilation, increased blood pressure, and increased force of the patellar reflex.[2][6][3][4] Tryptamine produced side effects including nausea, vomiting, dizziness, tingling sensations, sweating, and bodily heaviness among others as well.[2][4] Conversely, there were no changes in heart rate or respiratory rate.[4] The onset of the effects was rapid and the duration was very short.[5][6][3][4] This can be attributed to the very rapid metabolism of tryptamine by monoamine oxidase (MAO) and its very short elimination half-life.[5][6][3][4]

In animals, tryptamine, alone and/or in combination with a monoamine oxidase inhibitor (MAOI), produces behavioral changes such as hyperlocomotion and reversal of reserpine-induced behavioral depression.[2][5][53][54] In addition, it produces effects like hyperthermia, tachycardia, myoclonus, and seizures or convulsions, among others.[2][5][53][54] Findings on tryptamine and the head-twitch response in rodents have been mixed, with some studies reporting no effect,[55][56] some studies reporting induction of head twitches by tryptamine,[57][58][59] and others reporting that tryptamine actually antagonized 5-hydroxytryptophan (5-HTP)-induced head twitches.[53][55] Another study found that combination of tryptamine with an MAOI dose-dependently produced head twitches.[60] Head twitches in rodents are a behavioral proxy of psychedelic-like effects.[61][62] Many of the effects of tryptamine can be reversed by serotonin receptor antagonists like metergoline, metitepine (methiothepin), and cyproheptadine.[5][53][54][2] Conversely, the effects of tryptamine in animals are profoundly augmented by MAOIs due to inhibition of its metabolism.[5][54][2]

Tryptamine seems to also elevate prolactin and cortisol levels in animals and/or humans.[54]

The LD50Tooltip median lethal dose values of tryptamine in animals include 100 mg/kg i.p. in mice, 500 mg/kg s.c. in mice, and 223 mg/kg i.p. in rats.[63]

Pharmacokinetics

[edit]

Tryptamine produced endogenously or administered peripherally is readily able to cross the blood–brain barrier and enter the central nervous system.[54][53] This is in contrast to serotonin, which is peripherally selective.[54]

Tryptamine is metabolized by monoamine oxidase (MAO) to form indole-3-acetic acid (IAA).[54][5][53] Its metabolism is described as extremely rapid and its elimination half-life and duration as very short.[5][6][3][4] In addition, its duration is described as shorter than that of dimethyltryptamine (DMT).[2] Brain tryptamine levels are increased up to 300-fold by MAOIs in animals.[53] In addition, the effects of exogenous tryptamine are strongly augmented by monoamine oxidase inhibitors (MAOIs).[5][53]

Tryptamine is excreted in urine and its rate of urinary excretion has been reported to be pH-dependent.[4][7][8]

Chemistry

[edit]

Tryptamine is a substituted tryptamine derivative and trace amine and is structurally related to the amino acid tryptophan.

The experimental log P of tryptamine is 1.55.[63]

Derivatives

[edit]
Main article: Substituted tryptamine

The endogenous monoamine neurotransmitters serotonin (5-hydroxytryptamine or 5-HT) and melatonin (5-methoxy-N-acetyltryptamine), as well as trace amines like N-methyltryptamine (NMT), N,N-dimethyltryptamine (DMT), and bufotenin (N,N-dimethylserotonin), are derivatives of tryptamine.

A variety of drugs, including both naturally occurring and pharmaceutical substances, are derivatives of tryptamine. These include the tryptamine psychedelics like psilocybin, psilocin, DMT, and 5-MeO-DMT; tryptamine stimulants, entactogens, psychedelics, and/or antidepressants like α-methyltryptamine (αMT) and α-ethyltryptamine (αET); triptan antimigraine agents like sumatriptan; certain antipsychotics like oxypertine; and the sleep aid melatonin.

All tryptamine derivatives possess a modified 2-aminoethyl group and/or the addition of a substituent on the indole.

Various other drugs, including ergolines and lysergamides like the psychedelic lysergic acid diethylamide (LSD), the antimigraine agents ergotamine, dihydroergotamine, and methysergide, and the antiparkinsonian agents bromocriptine, cabergoline, lisuride, and pergolide; β-carbolines like harmine (some of which are monoamine oxidase inhibitors (MAOIs)); Iboga alkaloids like the hallucinogen ibogaine; yohimbans like the α2 blocker yohimbine; antipsychotics like ciclindole and flucindole; and the MAOI antidepressant metralindole, can all be thought of as cyclized tryptamine derivatives.

Drugs very closely related to tryptamines, but technically not tryptamines themselves, include certain triptans like avitriptan and naratriptan; the antipsychotics sertindole and tepirindole; and the MAOI antidepressants pirlindole and tetrindole.

References

[edit]
  1. ^ Lide, D. R., ed. (2005). CRC Handbook of Chemistry and Physics (85th ed.). CRC Press. pp. 3–564. ISBN 978-0-8493-0484-2.
  2. ^ a b c d e f g h i Martin, W. R.; Sloan, J. W. (1977). "Pharmacology and Classification of LSD-like Hallucinogens". Drug Addiction II. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 305–368. doi:10.1007/978-3-642-66709-1_3. ISBN 978-3-642-66711-4. MARTIN and SLOAN (1970) found that intravenously infused tryptamine increased blood pressure, dilated pupils, enhanced the patellar reflex, and produced perceptual distortions. [...] Tryptamine, but not DMT, increases locomotor activity in the mouse, while both antagonize reserpine depression (V ANE et al., 1961). [...] In the rat, tryptamine causes backward locomotion, Straub tail, bradypnea and dyspnea, and clonic convulsions (TEDESCHI et al., 1959). [...] Tryptamine produces a variety of changes in the cat causing signs of sympathetic activation including mydriasis, retraction of nictitating membrane, piloerection, motor signs such as extension of limbs and convulsions and affective changes such as hissing and snarling (LAIDLAW, 1912). [...]
  3. ^ a b c d e f g h i j Shulgin, A. (1997). Tihkal: The Continuation. Transform Press. #53. T. ISBN 978-0-9630096-9-2. Retrieved 17 August 2024. (with 250 mg, intravenously) "Tryptamine was infused intravenously over a period of up to 7.5 minutes. Physical changes included an increases in blood pressure, in the amplitude of the patellar reflex, and in pupillary diameter. The subjective changes are not unlike those seen with small doses of LSD. A point-by-point comparison between the tryptamine and LSD syndromes reveals a close similarity which is consistent with the hypothesis that tryptamine and LSD have a common mode of action."
  4. ^ a b c d e f g h i j k l m n Martin WR, Sloan JW (1970). "Effects of infused tryptamine in man". Psychopharmacologia. 18 (3): 231–237. doi:10.1007/BF00412669. PMID 4922520.
  5. ^ a b c d e f g h i j k l m n o p Jones RS (1982). "Tryptamine: a neuromodulator or neurotransmitter in mammalian brain?". Prog Neurobiol. 19 (1–2): 117–139. doi:10.1016/0301-0082(82)90023-5. PMID 6131482.
  6. ^ a b c d e f g h i j k l m n o p q r s t u v Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology (Berl). 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892. [Tryptamine (T): [...] Psychoactive effects: Psychoactive, short acting due to metabolism, increased blood pressure, similar to LSD
  7. ^ a b Franzen F, Gross H (June 1965). "Tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine". Nature. 206 (988): 1052. doi:10.1038/2061052a0. PMID 5839067.
  8. ^ a b Price J (December 1975). "The dependence of tryptamine excretion on urinary pH". Clin Chim Acta. 65 (3): 339–342. doi:10.1016/0009-8981(75)90259-4. PMID 1161.
  9. ^ a b "Tryptamine". pubchem.ncbi.nlm.nih.gov. Retrieved 2020-12-01.
  10. ^ a b c d Jenkins, Trisha A.; Nguyen, Jason C. D.; Polglaze, Kate E.; Bertrand, Paul P. (2016-01-20). "Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis". Nutrients. 8 (1): 56. doi:10.3390/nu8010056. ISSN 2072-6643. PMC 4728667. PMID 26805875.
  11. ^ Tylš, Filip; Páleníček, Tomáš; Horáček, Jiří (2014-03-01). "Psilocybin – Summary of knowledge and new perspectives". European Neuropsychopharmacology. 24 (3): 342–356. doi:10.1016/j.euroneuro.2013.12.006. ISSN 0924-977X. PMID 24444771. S2CID 10758314.
  12. ^ a b c Tittarelli, Roberta; Mannocchi, Giulio; Pantano, Flaminia; Romolo, Francesco Saverio (2015). "Recreational Use, Analysis and Toxicity of Tryptamines". Current Neuropharmacology. 13 (1): 26–46. doi:10.2174/1570159X13666141210222409. ISSN 1570-159X. PMC 4462041. PMID 26074742.
  13. ^ "The Ayahuasca Phenomenon". MAPS. 21 November 2014. Retrieved 2020-10-03.
  14. ^ a b Mousseau DD (March 1993). "Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders". Metab Brain Dis. 8 (1): 1–44. doi:10.1007/BF01000528. PMID 8098507.
  15. ^ a b Khan, Muhammad Zahid; Nawaz, Waqas (2016-10-01). "The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system". Biomedicine & Pharmacotherapy. 83: 439–449. doi:10.1016/j.biopha.2016.07.002. ISSN 0753-3322. PMID 27424325.
  16. ^ a b c d e Berry, Mark D.; Gainetdinov, Raul R.; Hoener, Marius C.; Shahid, Mohammed (2017-12-01). "Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges". Pharmacology & Therapeutics. 180: 161–180. doi:10.1016/j.pharmthera.2017.07.002. ISSN 0163-7258. PMID 28723415. S2CID 207366162.
  17. ^ a b c d e f Bhattarai, Yogesh; Williams, Brianna B.; Battaglioli, Eric J.; Whitaker, Weston R.; Till, Lisa; Grover, Madhusudan; Linden, David R.; Akiba, Yasutada; Kandimalla, Karunya K.; Zachos, Nicholas C.; Kaunitz, Jonathan D. (2018-06-13). "Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion". Cell Host & Microbe. 23 (6): 775–785.e5. doi:10.1016/j.chom.2018.05.004. ISSN 1931-3128. PMC 6055526. PMID 29902441.
  18. ^ a b Field, Michael (2003). "Intestinal ion transport and the pathophysiology of diarrhea". Journal of Clinical Investigation. 111 (7): 931–943. doi:10.1172/JCI200318326. ISSN 0021-9738. PMC 152597. PMID 12671039.
  19. ^ "Serotonin Receptor Agonists (Triptans)", LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, PMID 31644023, retrieved 2020-10-15
  20. ^ "New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression". UC Davis. 2020-12-09. Retrieved 2020-12-11.
  21. ^ ServiceDec. 9, Robert F. "Chemists re-engineer a psychedelic to treat depression and addiction in rodents". Science | AAAS. Retrieved 2020-12-11.{{cite web}}: CS1 maint: numeric names: authors list (link)
  22. ^ a b c d e Miller, Gregory M. (2011). "The Emerging Role of Trace Amine Associated Receptor 1 in the Functional Regulation of Monoamine Transporters and Dopaminergic Activity". Journal of Neurochemistry. 116 (2): 164–176. doi:10.1111/j.1471-4159.2010.07109.x. ISSN 0022-3042. PMC 3005101. PMID 21073468.
  23. ^ "Serotonin Synthesis and Metabolism". Sigma Aldrich. 2020.
  24. ^ "MetaCyc L-tryptophan degradation VI (via tryptamine)". biocyc.org. Retrieved 2020-12-11.
  25. ^ "PDSP Database". UNC (in Zulu). Retrieved 7 November 2024.
  26. ^ Liu, Tiqing. "BindingDB BDBM50024210 1H-indole-3-ethanamine::2-(1H-indol-3-yl)ethanamine::2-(3-indolyl)ethylamine::CHEMBL6640::tryptamine". BindingDB. Retrieved 7 November 2024.
  27. ^ a b c d Gainetdinov, Raul R.; Hoener, Marius C.; Berry, Mark D. (2018-07-01). "Trace Amines and Their Receptors". Pharmacological Reviews. 70 (3): 549–620. doi:10.1124/pr.117.015305. ISSN 0031-6997. PMID 29941461. S2CID 49411553.
  28. ^ a b c d e f Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorg Med Chem Lett. 24 (19): 4754–4758. doi:10.1016/j.bmcl.2014.07.062. PMC 4211607. PMID 25193229.
  29. ^ Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (September 1999). "Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells". Br J Pharmacol. 128 (1): 13–20. doi:10.1038/sj.bjp.0702751. PMC 1571597. PMID 10498829.
  30. ^ Anwar MA, Ford WR, Broadley KJ, Herbert AA (April 2012). "Vasoconstrictor and vasodilator responses to tryptamine of rat-isolated perfused mesentery: comparison with tyramine and β-phenylethylamine". Br J Pharmacol. 165 (7): 2191–2202. doi:10.1111/j.1476-5381.2011.01706.x. PMC 3413856. PMID 21958009.
  31. ^ Bradley PB, Humphrey PP, Williams RH (April 1985). "Tryptamine-induced vasoconstrictor responses in rat caudal arteries are mediated predominantly via 5-hydroxytryptamine receptors". Br J Pharmacol. 84 (4): 919–925. doi:10.1111/j.1476-5381.1985.tb17386.x. PMC 1987057. PMID 3159458.
  32. ^ "Microbiome-Lax May Relieve Constipation". GEN - Genetic Engineering and Biotechnology News. 2018-06-15. Retrieved 2020-12-11.
  33. ^ Yu, Ai-Ming; Granvil, Camille P.; Haining, Robert L.; Krausz, Kristopher W.; Corchero, Javier; Küpfer, Adrian; Idle, Jeffrey R.; Gonzalez, Frank J. (2003-02-01). "The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine". Journal of Pharmacology and Experimental Therapeutics. 304 (2): 539–546. doi:10.1124/jpet.102.043786. ISSN 0022-3565. PMID 12538805. S2CID 18279145.
  34. ^ a b Zucchi, R; Chiellini, G; Scanlan, T S; Grandy, D K (2006). "Trace amine-associated receptors and their ligands". British Journal of Pharmacology. 149 (8): 967–978. doi:10.1038/sj.bjp.0706948. ISSN 0007-1188. PMC 2014643. PMID 17088868.
  35. ^ Jing, Li; Li, Jun-Xu (2015-08-15). "Trace amine-associated receptor 1: a promising target for the treatment of psychostimulant addiction". European Journal of Pharmacology. 761: 345–352. doi:10.1016/j.ejphar.2015.06.019. ISSN 0014-2999. PMC 4532615. PMID 26092759.
  36. ^ a b Grandy, David K.; Miller, Gregory M.; Li, Jun-Xu (2016-02-01). ""TAARgeting Addiction" The Alamo Bears Witness to Another Revolution". Drug and Alcohol Dependence. 159: 9–16. doi:10.1016/j.drugalcdep.2015.11.014. ISSN 0376-8716. PMC 4724540. PMID 26644139.
  37. ^ a b c Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707.
  38. ^ a b c Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W.
  39. ^ Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026.
  40. ^ Forsyth, Andrea N (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines". ScholarWorks@UNO. Retrieved 4 November 2024.
  41. ^ Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE (April 2012). "Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters". The Journal of Pharmacology and Experimental Therapeutics. 341 (1): 251–262. doi:10.1124/jpet.111.188946. PMC 3364510. PMID 22271821.
  42. ^ a b Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2–3): 132–137. doi:10.1016/j.ejphar.2006.11.075. PMID 17223101.
  43. ^ Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836.
  44. ^ Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs". Eur J Pharmacol. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135.
  45. ^ Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
  46. ^ a b c Shimazu S, Miklya I (May 2004). "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28 (3): 421–427. doi:10.1016/j.pnpbp.2003.11.016. PMID 15093948. S2CID 37564231.
  47. ^ a b c Knoll J (August 2003). "Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives". Neurochem Res. 28 (8): 1275–1297. doi:10.1023/a:1024224311289. PMID 12834268.
  48. ^ Harsing LG, Knoll J, Miklya I (August 2022). "Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum". Int J Mol Sci. 23 (15): 8543. doi:10.3390/ijms23158543. PMC 9369307. PMID 35955676.
  49. ^ Harsing LG, Timar J, Miklya I (August 2023). "Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline". Int J Mol Sci. 24 (17): 13334. doi:10.3390/ijms241713334. PMC 10487936. PMID 37686140.
  50. ^ Knoll J (2001). "Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain". CNS Drug Rev. 7 (3): 317–45. doi:10.1111/j.1527-3458.2001.tb00202.x. PMC 6494119. PMID 11607046.
  51. ^ Yoneda F, Moto T, Sakae M, Ohde H, Knoll B, Miklya I, Knoll J (May 2001). "Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain". Bioorg Med Chem. 9 (5): 1197–1212. doi:10.1016/s0968-0896(01)00002-5. PMID 11377178.
  52. ^ Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I (December 1999). "(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain". British Journal of Pharmacology. 128 (8): 1723–1732. doi:10.1038/sj.bjp.0702995. PMC 1571822. PMID 10588928.
  53. ^ a b c d e f g h Kellar, Kenneth J.; Cascio, Caren S. "Tryptamine and Phenylethylamine Recognition Sites in Brain". Receptor Binding. New Jersey: Humana Press. pp. 119–138. doi:10.1385/0-89603-078-4:119. ISBN 0-89603-078-4.
  54. ^ a b c d e f g h Murphy, D. L.; Tamarkin, L.; Garrick, N. A.; Taylor, P. L.; Markey, S. P. (1985). "Trace Indoleamines in the Central Nervous System". Neuropsychopharmacology of the Trace Amines. Totowa, NJ: Humana Press. pp. 343–360. doi:10.1007/978-1-4612-5010-4_36. ISBN 978-1-4612-9397-2.
  55. ^ a b Jones RS (June 1981). "In vivo pharmacological studies on the interactions between tryptamine and 5-hydroxytryptamine". Br J Pharmacol. 73 (2): 485–493. doi:10.1111/j.1476-5381.1981.tb10447.x. PMC 2071674. PMID 6972243.
  56. ^ Yamada J, Sugimoto Y, Horisaka K (January 1987). "The behavioural effects of intravenously administered tryptamine in mice". Neuropharmacology. 26 (1): 49–53. doi:10.1016/0028-3908(87)90043-8. PMID 3561719.
  57. ^ Haberzettl R, Bert B, Fink H, Fox MA (November 2013). "Animal models of the serotonin syndrome: a systematic review". Behav Brain Res. 256: 328–345. doi:10.1016/j.bbr.2013.08.045. PMID 24004848.
  58. ^ Sugimoto Y, Yamada J, Horisaka K (January 1986). "Effect of tryptamine on the behavior of mice". J Pharmacobiodyn. 9 (1): 68–73. doi:10.1248/bpb1978.9.68. PMID 2940357.
  59. ^ Orikasa S, Sloley BD (1988). "Effects of 5,7-dihydroxytryptamine and 6-hydroxydopamine on head-twitch response induced by serotonin, p-chloroamphetamine, and tryptamine in mice". Psychopharmacology (Berl). 95 (1): 124–131. doi:10.1007/BF00212780. PMID 3133691.
  60. ^ Irons, Jane; Robinson, C. M.; Marsden, C. A. (1984). "5ht Involvement in Tryptamine Induced Behaviour in Mice". Neurobiology of the Trace Amines. Totowa, NJ: Humana Press. pp. 423–427. doi:10.1007/978-1-4612-5312-9_35. ISBN 978-1-4612-9781-9.
  61. ^ Canal CE, Morgan D (2012). "Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model". Drug Test Anal. 4 (7–8): 556–576. doi:10.1002/dta.1333. PMC 3722587. PMID 22517680.
  62. ^ Kozlenkov, Alexey; González-Maeso, Javier (2013). "Animal Models and Hallucinogenic Drugs". The Neuroscience of Hallucinations. New York, NY: Springer New York. pp. 253–277. doi:10.1007/978-1-4614-4121-2_14. ISBN 978-1-4614-4120-5.
  63. ^ a b "Tryptamine". PubChem. Retrieved 7 November 2024.
[edit]
Retrieved from "https://wiki.eso.workers.dev/w/index.php?title=Tryptamine&oldid=1263709837"